RxDoctor Payments Data

Deepak Sambhara, MD

Ophthalmology · Wausau, WINPI 1083024574

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 34.0% of the total. 2025 is the largest year on record at $167,222, more than ten times the $137 reported in 2019. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$388,056in general payments, 2019–2025

Across 333 payments — averaging $1165.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$132K
  • Regeneron Healthcare Solutions, Inc.$98K
  • Astellas Pharma US Inc$83K
  • Ocular Therapeutix, Inc.$21K
  • Regeneron$16K
  • Genentech USA, Inc.$12K
  • plus $26K from 13 others
$1,595,737in research payments, 2019–2025

Across 77 payments — averaging $20,724 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ocular Therapeutix, Inc.$1.6M
  • Regeneron$7K
  • F. Hoffmann-la Roche AG$6K

What the payments were for

  • Consulting fees$98,75425%
  • Speaking & faculty fees$229,22759%
  • Travel & lodging$48,64513%
  • Food & beverage$11,4303%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$388,056 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$6,056,190
Medicare patients
652
Services billed
111,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate32$1,450
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$151
Latanoprost11$90

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →